stock (Page 12)

Md Saiful Islam Khan/iStock via Getty Images Annexon (NASDAQ:ANNX) shares traded higher on Wednesday after the company released additional data from its completed pivotal Phase 3 trial for its lead asset, ANX005, against the neurological disorder Guillain-Barré syndrome (GBS). Early this month, citing topline results from the study, the Brisbane,Continue Reading

OneO2 Stock futures held steady on Wednesday amid a pause in the global chip sell-off and significant rebounds in Nvidia and other tech stocks. Market participants look ahead to PCE price data, the Fed’s preferred inflation measure, and the 2024 first presidential debate. Here are some of Wednesday’s biggest stockContinue Reading

Grandbrothers/iStock Editorial via Getty Images Ionis Pharmaceuticals (NASDAQ:IONS) traded higher Tuesday after the U.S. FDA accepted to review a marketing application for its anti-lipid therapy olezarsen, targeted at a rare genetic condition known as familial chylomicronemia syndrome (FCA). Granting priority review for Ionis’ (IONS) New Drug Application (NDA) for olezarsen,Continue Reading

Sundry Photography/iStock Editorial via Getty Images Johnson & Johnson (NYSE:JNJ) has discontinued a Phase 2 trial for its blockbuster arthritis therapy Tremfya in patients with an autoimmune disorder called giant cell arteritis after the study failed to meet the primary goal, according to updated data from a federal register ofContinue Reading

Anne Czichos Shares of Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY) fell in European trading on Tuesday after the German drugmaker said it would discontinue a late-stage trial for its head and neck cancer therapy xevinapant as its early results indicated a potential failure. The decision comes after the study’s data monitoring committeeContinue Reading